|
Aurobindo Pharma had gone public in 1995 by listing its shares in various stock exchanges in the country. Aurobindo Pharma created a name for itself in manufacture of bulk actives, its area of core competence. After ensuring a firm foundation of cost effective production capabilities and a clutch of loyal customers, the Company has entered the high margin speciality generic formulations segment with a global marketing network. The Company is the market leader in the semi-synthetic penicillin drugs. It has a presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc.
|
